Discovery of 4-Aryl-7-hydroxyindoline-based P2Y1 antagonists as novel antiplatelet agents

Journal of Medicinal Chemistry

Volumn 57, Issue 14, 2014, Pages 6150-6164

  Yang, Wu ^a   Wang, Yufeng ^a   Lai, Amy ^a   Qiao, Jennifer X ^a   Wang, Tammy C ^a   Hua, Ji ^b   Price, Laura A ^b   Shen, Hong ^c   Chen, Xue Qing ^c   Wong, Pancras ^b   Crain, Earl ^b   Watson, Carol ^b   Huang, Christine S ^c   Seiffert, Dietmar A ^b   Rehfuss, Robert ^b   Wexler, Ruth R ^a   Lam, Patrick Y S ^a  

^a Bristol Myers Squibb   (United States)

^b Discovery Biology   (United States)

^c BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2 [5 FLUORO 7 HYDROXY 3,3 DIMETHYL 4 [5 (TRIFLUOROMETHYL) PYRIDIN 2 YL] 2,3 DIHYDRO 1H INDOL 1 YL]PHENYL]3 [4 (TRIFLUOROMETHOXY)PHENYL]UREA; 1 [2 [4 (2,6 DIFLUOROPYRIDIN 4 YL) 5 FLUORO 7 HYDROXY 3,3 DIMETHYL 2,3 DIHYDRO 1H INDOL 1 YL]PHENYL] 3 [4 (TRIFLUOROMETHOXY)PHENYL]UREA; 1 [2 [4 (4 CHLOROPHENYL) 5 FLUORO 7 HYDROXY 3,3 DIMETHYL 2,3 DIHYDRO 1H INDOL 1 YL]PHENYL] 3 [4 (TRIFLUOROMETHOXY)PHENYL]UREA; 1 [2 [4 (4 CHLOROPHENYL) 6 FLUORO 7 HYDROXY 3,3 DIMETHYL 2,3 DIHYDRO 1H INDOL 1 YL]PHENYL] 3 [4 (TRIFLUOROMETHOXY)PHENYL]UREA; 1 [2 [4 (4 FLUOROPHENYL) 7 HYDROXY 3,3 DIMETHYL 2,3 DIHYDRO 1H INDOL 1 YL]PHENYL] 3 (2 METHYL 1,3 THIAZOL 4 YL)UREA; 1 [2 [4 (4 FLUOROPHENYL) 7 HYDROXY 3,3 DIMETHYL 2,3 DIHYDRO 1H INDOL 1 YL]PHENYL] 3 [4 [1 (2-METHYLPROPYL)PYRROLIDIN 2 YL]PHENYL]UREA; 1 [2 [4 (5 CHLOROPYRAZIN 2 YL) 5 FLUORO 7 HYDROXY 3,3 DIMETHYL 2,3 DIHYDRO 1H INDOL 1 YL]PHENYL] 3 [4 (TRIFLUOROMETHOXY)PHENYL]UREA; 1 [2 [4 (5 CHLOROTHIOPHEN 2 YL) 5 FLUORO 7 HYDROXY 3,3 DIMETHYL 2,3 DIHYDRO 1H INDOL 1 YL]PHENYL] 3 [4 (TRIFLUOROMETHOXY)PHENYL]UREA; 1 [2 [5 FLUORO 4 (4 FLUOROPHENYL) 7 HYDROXY 3,3 DIMETHYL 2,3 DIHYDRO 1H INDOL 1 YL]PHENYL] 3 [4 (TRIFLUOROMETHOXY)PHENYL]UREA; 1 [2 [5 FLUORO 4 (5 FLUOROPYRIMIDIN 2 YL) 7 HYDROXY 3,3 DIMETHYL 2,3 DIHYDRO 1H INDOL 1 YL]PHENYL] 3 [4 (TRIFLUOROMETHOXY)PHENYL]UREA; 1 [2 [5 FLUORO 7 HYDROXY 3,3 DIMETHYL 4 [6 (TRIFLUOROMETHYL)PYRIDIN 3 YL] 2,3 DIHYDRO 1H INDOL 1 YL]PHENYL] 3 [4 (TRIFLUOROMETHOXY)PHENYL]UREA; 1 [2 [6 FLUORO 4 (4 FLUOROPHENYL) 7 HYDROXY 3,3 DIMETHYL 2,3 DIHYDRO 1H INDOL 1 YL]PHENYL] 3 [4 (TRIFLUOROMETHOXY)PHENYL]UREA; 3 (2 CHLORO 1,3 THIAZOL 4 YL) 1 [2 [4 (4 FLUOROPHENYL) 7 HYDROXY 3,3 DIMETHYL 2,3 DIHYDRO 1H INDOL 1YL]PHENYL]UREA; 3 [2 [4 (2 FLUOROPHENYL) 7 HYDROXY 3,3 DIMETHYL 2,3 DIHYDRO 1H INDOL 1 YL]PHENYL] 1 [4 (TRIFLUOROMETHOXY)PHENYL]UREA; 3 [2 [4 (2,4 DIFLUOROPHENYL) 7 HYDROXY 3,3 DIMETHYL 2,3 DIHYDRO 1H INDOL 1 YL]PHENYL] 1 [4 (TRIFLUOROMETHOXY)PHENYL]UREA; 3 [2 [4 (3 FLUOROPHENYL) 7 HYDROXY 3,3 DIMETHYL 2,3 DIHYDRO 1H INDOL 1 YL]PHENYL] 1 [4 (TRIFLUOROMETHOXY)PHENYL]UREA; 3 [2 [4 (3,4 DIFLUOROPHENYL) 7 HYDROXY 3,3 DIMETHYL 2,3 DIHYDRO 1H INDOL 1 YL]PHENYL] 1 [4 (TRIFLUOROMETHOXY)PHENYL]UREA; 3 [2 [4 (3,5 DIFLUOROPHENYL) 7 HYDROXY 3,3 DIMETHYL 2,3 DIHYDRO 1H INDOL 1 YL]PHENYL] 1 [4 (TRIFLUOROMETHOXY)PHENYL]UREA; 3 [2 [4 (4 CHLOROPHENYL) 7 HYDROXY 3,3 DIMETHYL 2,3 DIHYDRO 1H INDOL 1 YL]PHENYL] 1 [4 (TRIFLUOROMETHOXY)PHENYL]UREA; 3 [2 [4 (4 FLUOROPHENYL) 7 HYDROXY 3,3 DIMETHYL 2,3 DIHYDRO 1H INDOL 1 YL]PHENYL] 1 [4 (TRIFLUOROMETHOXY)PHENYL]UREA; 3 [2 [7 HYDROXY 3,3 DIMETHYL 4 [4 (TRIFLUOROMETHYL)PHENYL] 2,3 DIHYDRO 1H INDOL 1 YL]PHENYL] 1 [4 (TRIFLUOROMETHOXY)PHENYL]UREA; 3 [4 [1 (2,2 DIMETHYLPROPYL)PYRROLIDIN 2 YL]PHENYL] 1 [2 [4 (4 FLUOROPHENYL) 7 HYDROXY 3,3 DIMETHYL 2,3 DIHYDRO 1H INDOL 1 YL]PHENYL]UREA; 3 [5 CHLORO [1,3]THIAZOLO[5,4 B]PYRIDIN 2 YL] 1 [2 [4 (4 FLUOROPHENYL) 7 HYDROXY 3,3 DIMETHYL 2,3 DIHYDRO 1H INDOL 1 YL]PHENYL]UREA; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; PRASUGREL; PURINERGIC P2Y RECEPTOR ANTAGONIST; PURINERGIC P2Y1 RECEPTOR ANTAGONIST; PURINERGIC P2Y12 RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICOAGULATION; ARTERY THROMBOSIS; ARTICLE; BLEEDING; BLOOD CLOTTING; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG POTENCY; DRUG SOLUBILITY; DRUG STABILITY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER MICROSOME; NONHUMAN; OXIDATION; RAT; STRUCTURE ACTIVITY RELATION; THROMBOCYTE AGGREGATION;

ANIMALS; BLOOD COAGULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DISCOVERY; HUMANS; INDOLES; MICE; MICROSOMES, LIVER; MOLECULAR STRUCTURE; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RABBITS; RATS; RECEPTORS, PURINERGIC P2Y1; STRUCTURE-ACTIVITY RELATIONSHIP; THROMBOSIS;

EID: 84904964810     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm5006226     Document Type: Article

References (33)

1. Jin, J.; Kunapuli, S. P. Coactivation of two different G protein-coupled receptors is essential for ADP-induced platelet aggregation Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 8070-8074
2. Kahner, B. N.; Shankar, H.; Murugappan, S.; Prasad, G. L.; Kunapuli, S. P. Nucleotide receptor signaling in platelets J. Thromb. Haemostasis 2006, 4, 2317-2326
3. Kunapuli, S. P.; Dorsam, R. T.; Kim, S.; Quinton, T. M. Platelet purinergic receptors Curr. Opin. Pharmacol. 2003, 3, 175-80
4. Hollopeter, G.; Jantzen, H. M.; Vincent, D.; Li, G.; England, L.; Ramakrishnan, V.; Yang, R. B.; Nurden, P.; Nurden, A.; Julius, D.; Conley, P. B. Identification of the platelet ADP receptor targeted by antithrombotic drugs Nature 2001, 409, 202-207
5. Pereillo, J. M.; Maftouh, M.; Andrieu, A.; Uzabiaga, M. F.; Fedeli, O.; Savi, P.; Pascal, M.; Herbert, J. M.; Maffrand, J. P.; Picard, C. Structure and stereochemistry of the active metabolite of clopidogrel Drug Metab. Dispos. 2002, 30, 1288-1295
6. 12 antagonist AZD6140 with Aspirin in patients with atherosclerosis: A double-blind comparison to clopidogrel with aspirin Eur. Heart J. 2006, 27, 1038-1047
7. Jernberg, T.; Payne, C. D.; Winters, K. J.; Darstein, C.; Brandt, J. T.; Jakubowski, J. A.; Naganuma, H.; Siegbahn, A.; Wallentin, L. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease Eur. Heart J. 2006, 27, 1166-117
8. Jakubowski, J. A.; Winters, K. J.; Naganuma, H.; Wallentin, L. Prasugrel: A novel thienopyridine antiplatelet agent. A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile Cardiovasc. Drug Rev. 2007, 25, 357-374
9. 12 receptor antagonist for the prevention of thrombosis Bioorg. Med. Chem. Lett. 2007, 17, 6013-6018
10. 12 Inhibitors Circulation 2010, 121, 171-179
11. 1 receptor-null mice J. Clin Invest. 1999, 104, 1731-1737
12. 1-deficient mice Nat. Med. 1999, 5, 1199-1202
13. 1 receptor in tissue factor-induced thrombin-dependent acute thromboembolism Circulation 2001, 103, 718-723
14. 1 antagonist MRS-2179 Cardiovasc. Drug Rev. 2003, 21, 67-76
15. 1 receptor with strong antithrombotic activity in mice J. Pharmacol. Exp. Ther. 2006, 316, 556-563
16. 1 deletion or antagonism protects mice from vena cava thrombosis J. Thromb. Thrombolysis 2012, 34, 199-207
17. 1 antagonism on thrombosis, bleeding and ex vivo platelet aggregation in rabbits. Circulation 2006, 114, II-248, abstract 1310.
18. 1 receptor antagonists as novel antithrombotic agents Bioorg. Med. Chem. Lett. 2008, 18, 3338-3343
19. 1 receptor antagonists Bioorg. Med. Chem. Lett. 2008, 18, 6222-6226
20. 1 receptor Comb. Chem. High Throughput Screening 2008, 11, 410-419
21. 1 receptor antagonists Bioorg. Med. Chem. Lett. 2010, 20, 4104-4107
22. 1 receptor antagonists Bioorg. Med. Chem. 2012, 20, 5254-5261
23. Baqi, Y.; Mueller, C. E. Convergent synthesis of the potent P2Y receptor antagonist MG 50-3-1 based on a regioselective Ullmann coupling reaction Molecules 2012, 17, 2599-2615
24. 1 antagonists J. Med. Chem. 2013, 56, 1704-1714
25. 1 antagonists with improved aqueous solubility Bioorg. Med. Chem. Lett. 2013, 23, 3239-3241
26. 1 receptor Bioorg. Med. Chem. Lett. 2013, 23, 3519-3522
27. 1 antagonists as novel antiplatelet agents Bioorg. Med. Chem. Lett. 2013, 23, 4206-4209
28. Ruel, R.; L'Heureux, A.; Thibeault, C.; Lapointe, P.; Martel, A.; Qiao, J. X.; Hua, J.; Price, L. A.; Wu, Q.; Chang, M.; Zheng, J.; Haung, C. S.; Wexler, R. R.; Rehfuss, R.; Lam, P. Y. S. Potent P2Y1 urea antagonists bearing various cyclic amine scaffolds Bioorg. Med. Chem. Lett. 2013, 23, 6825-6828
29. 1 antagonist J. Med. Chem. 2013, 56, 9275-9295
30. Jeon, Y. T.; Yang, W.; Qiao, J. X.; Li, L.; Ruel, R.; Thibault, C.; Hiebert, S.; Wang, T.; Wang, Y.; Liu, Y.; Clark, C. G.; Wong, H. S.; Zhu, J.; Wu, D.-R.; Sun, D.; Chen, B.; Mathur, A.; Chacko, S. A.; Malley, M.; Chen, X.; Shen, H.; Huang, C. S.; Schumacher, W. A.; Bostwick, J. S.; Stewart, A. B.; Price, L. A.; Hua, J.; Li, D.; Levesque, P. C.; Seiffert, D. A.; Rehfuss, R.; Wexler, R.; Lam, P. Y. S. Identification of 1-{2-[4-chloro-1′-(2,2- dimethylpropyl)-7-hydroxy-1,2-dihydrospiro[indole-3,4′-piperidine]-1-yl] phenyl}-3-{5-chloro-[1,3]thiazolo[5,4-b]pyridin-2-yl}urea (BMS-816106), a potent, efficacious and orally available P2Y1 antagonist as an antiplatelet agent Bioorg. Med. Chem. Lett. 2014, 24, 1294-1298
31. Watanabe, T.; Schulz, D.; Morisseau, C.; Hammock, B. D. High-throughput pharmacokinetic method: Cassette dosing in mice associated with minuscule serial bleedings and LC/MS/MS analysis Anal. Chim. Acta 2006, 559, 37-44
32. Wong, P. C.; Crain, E. J.; Watson, C. A.; Hua, J.; Schumacher, W. A.; Rehfuss, R. Clopidogrel versus prasugrel in rabbits: Effects on thrombosis, hemostasis, platelet function and response variability Thromb. Haemostasis 2009, 101, 108-115
33. 12 receptor antagonismon thrombosis and bleeding in rabbits. 2013, European Society of Cardiology Congress, abstract number 81822.